Related Experiment Videos
Current concepts in the treatment of cardiac arrhythmias
Insights
Patients with impaired left ventricular function and ventricular arrhythmias are at high risk for sudden cardiac death. Indoramin, an alpha 1-antagonist, may offer antiarrhythmic benefits without adverse electrophysiologic effects.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Patients with specific cardiac conditions, including coronary artery disease and idiopathic dilated cardiomyopathy, face elevated risks of sudden cardiac death.
- Frequent and complex ventricular ectopy, particularly in conjunction with impaired left ventricular function, signifies a high-risk profile for sudden cardiac death.
- Recent myocardial infarction further exacerbates the risk of sudden cardiac death in coronary patients with ventricular ectopy.
Purpose of the Study:
- To evaluate the potential of the alpha 1-antagonist indoramin as a therapeutic agent for patients at risk of sudden cardiac death.
- To investigate the antiarrhythmic properties of indoramin in patient groups with left ventricular impairment and ventricular arrhythmias.
- To assess the electrophysiologic effects of indoramin, specifically its impact on reflex tachycardia, sinus node function, and atrioventricular/intraventricular conduction.
Main Methods:
- Review of patient populations at risk for sudden cardiac death, including those with coronary artery disease and idiopathic dilated cardiomyopathy.
- Identification of frequent ventricular tachycardias and ventricular pairs as indicators of high risk.
- Assessment of indoramin's effects in therapeutic doses, focusing on its ability to inhibit reflex tachycardia and its electrophysiologic profile.
Main Results:
- Indoramin effectively prohibited reflex tachycardia at therapeutic doses.
- No significant additional electrophysiologic effects were observed with indoramin treatment.
- Indoramin demonstrated no adverse effects on sinus node function, atrioventricular conduction, or intraventricular conduction.
Conclusions:
- Indoramin presents a potential therapeutic option for patients with left ventricular impairment and ventricular arrhythmias who are at risk of sudden cardiac death.
- The drug's ability to mitigate reflex tachycardia without negatively impacting cardiac conduction pathways suggests a favorable safety profile.
- Further investigation into indoramin's antiarrhythmic efficacy in these high-risk patient groups is warranted.
Abstract:
Attention has been paid to the recognition of patients at risk of sudden cardiac death. Whereas the long-term prognosis of healthy subjects with frequent and complex ventricular premature complexes is similar to that of the normal population, coronary patients with frequent and complex ectopy are at high risk of sudden cardiac death; in this group, recent myocardial infarction and impaired left ventricular function increase the likelihood for sudden death. In a similar way, patients with idiopathic dilated cardiomyopathy and reduced left ventricular function, in whom frequent episodes of ventricular tachycardias or ventricular pairs are detected, are at high risk of sudden death. These patient groups with left ventricular impairment may potentially be treated with the alpha 1-antagonist indoramin, which has exhibited antiarrhythmic properties in animal experiments. In a therapeutic dose, indoramin prohibited reflex tachycardia but did not show any additional electrophysiologic effects. Therefore, no adverse effects on sinus node function or on atrioventricular conduction, or intraventricular conduction must be expected during therapy with indoramin.